FDA Clears Dexcom Stelo OTC CGM for Children
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
overall survival
Advertisement
Menarini Reports Positive Phase 3 SENTRY Data at EHA
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Advertisements
OS Therapies Advances OST-HER2 Ahead of ASCO 2026 Presentation
NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...
Johnson & Johnson Reports Strong Survival Data for RYBREVANT
CHICAGO, Ill., May 29, 2026 Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study,...
Merck Sac-TMT Trial Shows Survival Benefit in Cancer
Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...
LOQTORZI + Chemo Nearly Doubles Survival in NPC at Six Years
REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...
Advertisement
